Subscribe to
our newsletters

Subscribe to our newsletters!

Subscribe to our newsletter and get the latest news from the Nordics straight to your inbox.

Search in Nordic Life Science Insight

-
June 9, 2021
NDA

Are you attending the Virtual DIA 2021 Global Annual Meeting?

Are you attending the Virtual DIA 2021 Global Annual Meeting?

-
NDA
-
June 9, 2021

We would love to connect with you during the DIA and discuss how we can support you to optimise your path to market approval.


Working together we can:

  • Accelerate your drug development program to reduce your time to approval
  • Optimise the management of the regulatory process to provide accurate and predictable outcomes
  • Reduce your risks and increase the probability of gaining Market Authorization

Don't miss our  great speakers sharing their knowledge in different forums throughout the conference:



Dr Steffen Thirstrup - NDA Advisory Board Director & John Ellis, Communications Coach, PharmApprove, NDA Group

A tutorial on Tuesday, June 22 • 09:30 – 12:30 EDT – Tutorial (Short Course)

025A: #025A: Optimizing your interaction with EU Regulatory Authorities: How to Prepare and Perform



Shelley Gandhi, Patient Safety & Pharmacovigilance Director, NDA Group

A session on 17th June • 13:00 -14:00 EDT  On-Demand and will be available anytime for viewing

OD: Safety Compliance

Clinical Trial Regulation is an Opportunity to Revisit Compliance at the Pharmacovigilance and GCP Interface



Dr Brian Edwards, Principal Consultant, NDA Group

Two Sessions - Semi-Live and will include live Q&A with our Speakers.

Monday, June 28 • 16:00 - 17:00 EDT
#SL: A Journey of Interdisciplinary Collaboration to Improve Safety Evaluation in Drug Development

Tuesday, June 29 • 14:00 - 15:00 EDT

#L: Systems Thinking: A better Way of Safety Management Planning



Click here to download the full programme.

Last updated:
June 9, 2021

NDA

NDA is a world leading drug development consultancy with a dedicated team of over 150 consultants supported by an expert network and a specialist Advisory Board. Our goal is to streamline drug development in order to accelerate patient access to important medical therapies.

Click here to read more about us!

We would love to connect with you during the DIA and discuss how we can support you to optimise your path to market approval.


Working together we can:

  • Accelerate your drug development program to reduce your time to approval
  • Optimise the management of the regulatory process to provide accurate and predictable outcomes
  • Reduce your risks and increase the probability of gaining Market Authorization

Don't miss our  great speakers sharing their knowledge in different forums throughout the conference:



Dr Steffen Thirstrup - NDA Advisory Board Director & John Ellis, Communications Coach, PharmApprove, NDA Group

A tutorial on Tuesday, June 22 • 09:30 – 12:30 EDT – Tutorial (Short Course)

025A: #025A: Optimizing your interaction with EU Regulatory Authorities: How to Prepare and Perform



Shelley Gandhi, Patient Safety & Pharmacovigilance Director, NDA Group

A session on 17th June • 13:00 -14:00 EDT  On-Demand and will be available anytime for viewing

OD: Safety Compliance

Clinical Trial Regulation is an Opportunity to Revisit Compliance at the Pharmacovigilance and GCP Interface



Dr Brian Edwards, Principal Consultant, NDA Group

Two Sessions - Semi-Live and will include live Q&A with our Speakers.

Monday, June 28 • 16:00 - 17:00 EDT
#SL: A Journey of Interdisciplinary Collaboration to Improve Safety Evaluation in Drug Development

Tuesday, June 29 • 14:00 - 15:00 EDT

#L: Systems Thinking: A better Way of Safety Management Planning



Click here to download the full programme.

Last updated:
June 9, 2021

NDA

NDA is a world leading drug development consultancy with a dedicated team of over 150 consultants supported by an expert network and a specialist Advisory Board. Our goal is to streamline drug development in order to accelerate patient access to important medical therapies.

Click here to read more about us!